C2N is a biotechnology company focused on developing innovative solutions for neurodegenerative diseases, particularly Alzheimer's disease. The company specializes in the discovery and commercialization of diagnostic tests and therapeutic products that aim to improve patient outcomes and enhance understanding of these complex conditions. One of C2N's notable products is the C2N-8A test, which measures specific biomarkers in the blood to help assess the risk of Alzheimer's disease. By providing valuable insights into disease progression, C2N aims to support healthcare professionals in making informed decisions regarding patient care and treatment options.